Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Does Fasting Plasma Glucose Values 5.1-5.6 Mmol/L in the First Trimester of Gestation a Matter? Publisher



Ramezani Tehrani F1 ; Farzadfar F2 ; Hosseinpanah F3 ; Rahmati M1 ; Firouzi F1 ; Abedini M4 ; Hadaegh F5 ; Valizadeh M3 ; Torkestani F6 ; Khalili D5 ; Solaymanidodaran M7 ; Bidhendiyarandi R8 ; Bakhshandeh M9 ; Ostovar A10 Show All Authors
Authors
  1. Ramezani Tehrani F1
  2. Farzadfar F2
  3. Hosseinpanah F3
  4. Rahmati M1
  5. Firouzi F1
  6. Abedini M4
  7. Hadaegh F5
  8. Valizadeh M3
  9. Torkestani F6
  10. Khalili D5
  11. Solaymanidodaran M7
  12. Bidhendiyarandi R8
  13. Bakhshandeh M9
  14. Ostovar A10
  15. Dovom MR1
  16. Amiri M1
  17. Azizi F11
  18. Behboudigandevani S12
Show Affiliations
Authors Affiliations
  1. 1. Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Infertility and Cell Therapy Office, Transplant & Disease Treatment Center, Ministry of Health and Medical Education, Tehran, Iran
  5. 5. Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Faculty of Medicine, Shahed University, Tehran, Iran
  7. 7. Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
  9. 9. Family Health Department, Ministry of Health and Medical Education, Tehran, Iran
  10. 10. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  11. 11. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  12. 12. Faculty of Nursing and Health Sciences, Nord University, Bodo, Norway

Source: Frontiers in Endocrinology Published:2023


Abstract

Objectives: The aim of the study was to investigate the effect of treatment on pregnancy outcomes among women who had fasting plasma glucose (FPG) 5.1-5.6 mmol/l in the first trimester of pregnancy. Methods: We performed a secondary-analysis of a randomized community non-inferiority trial of gestational diabetes mellitus (GDM) screening. All pregnant women with FPG values range 5.1-5.6 mmol/l in the first trimester of gestation were included in the present study (n=3297) and classified to either the (i) intervention group who received treatment for GDM along with usual prenatal care (n=1,198), (ii) control group who received usual-prenatal-care (n=2,099). Macrosomia/large for gestational age (LGA) and primary cesarean-section (C-S) were considered as primary-outcomes. A modified-Poisson-regression for binary outcome data with a log link function and robust error variance was used to RR (95%CI) for the associations between GDM status and incidence of pregnancy outcomes. Results: The mean maternal age and BMI of pregnant women in both study groups were similar. There were no statistically significant differences in the adjusted risks of adverse pregnancy outcomes, including macrosomia, primary C-S, preterm birth, hyperbilirubinemia, preeclampsia, NICU-admission, birth trauma, and LBW both groups. Conclusions: It is found that treating women with first-trimester FPG values of 5.1-5.6 mmol/l could not improve adverse pregnancy outcomes including macrosomia, Primary C-S, Preterm birth, hypoglycemia, hypocalcemia, preeclampsia, NICU admission, Birth trauma and LBW. Therefore, extrapolating the FPG cut-off point of the second trimester to the first –which has been proposed by the IADPSG, might therefore not be appropriate. Clinical Trial Registration: https://www.irct.ir/trial/518, identifier IRCT138707081281N1. Copyright © 2023 Ramezani Tehrani, Farzadfar, Hosseinpanah, Rahmati, Firouzi, Abedini, Hadaegh, Valizadeh, Torkestani, Khalili, Solaymani-Dodaran, Bidhendi-Yarandi, Bakhshandeh, Ostovar, Dovom, Amiri, Azizi and Behboudi-Gandevani.